Rodríguez-Revilla IC, Corvera-Behar G, Espinosa-Arce CB, García-De la Cruz MA

Language: Spanish
References: 22
Page: 7-13
PDF size: 181.30 Kb.

ABSTRACT

Objective: To assess the efficacy of third-generation bisphosphonates in relieving or stopping the progression of superficial hearing loss of otosclerosis in early stage.
Materials and Methods: A retrospective, descriptive study conducted at the Mexican Institute of Otology and Neurotology including patients with diagnosis of early otosclerosis and hearing loss in low tones who started treatment with risedronate 35 mg once a week for 6 months and audiometry at the end of treatment. Statistical analysis: paired Student t test.
Results: There were included 20 patients: 12 women and 8 men. Average age was of 44 years; 29 ears were evaluated: 16 right side and 13 left side. Air conduction: low tones average pretreatment was 31.1 dB and post-treatment 24.1 dB (p ‹ 0.05). Bone conduction: low tones average was 12.5 dB pretreatment and 9.1 dB post-treatment (p = ns). No significant changes were found in the average of all frequencies or in the pure tone average in air or bone conduction because our patients, being selected at the early stage of the disease, had no hearing compromise in medium and high tones.
Conclusions: Third-generation bisphosphonates contribute to reduce hearing loss in early stages of otosclerosis. Further long-term studies with periodic monitoring are needed to corroborate improvement or stabilization of hearing and standardize the optimal treatment time.

REFERENCES

1. Chole RA, McKenna M. Pathophysiology of otosclerosis. OtolNeurotol. 2001; 22 (2): 249-57. doi: 10.1097/00129492- 200103000-00023.

2. Guía práctica para el diagnóstico y tratamiento de otoesclerosis,México: Secretaría de Salud, 2011. http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/537_GPC_Otosclerosis/GER_Otoscleoris.

3. McKenna MJ, Kristiansen AG. Molecular biology ofotosclerosis. Adv Otorhinolaryngol 2007; 65: 68-74. doi:10.1159/000098674.

4. Declau F, Van Spaendonck M, Timmermans JP, Michaels L,Liang J, Qiu JP, et al. Prevalence of otosclerosis in an unselectedseries of temporal bones. Otol Neurotol 2001; 22(5): 596-602. doi: 10.1097/00129492-200109000-00006.

5. Crompton M, Cadge BA, Ziff JL, Mowat AJ, Nash R, LavyJA, et al. The Epidemiology of Otosclerosis in a BritishCohort. Otol Neurotol 2019; 40 (1): 22-30. doi: 10.1097/MAO.0000000000002047.

6. Foster MF, Backous DD. Clinical evaluation of the patientwith otosclerosis. Otolaryngol Clin North Am 2018; 51 (2):319-326. doi: 10.1016/j.otc.2017.11.004.

7. De Oliveira Penido N, de Oliveira Vicente A. Medical managementof otosclerosis. Otolaryngol Clin North Am 2018;51 (2): 441-452. doi: 10.1016/j.otc.2017.11.006.

8. Gros A, Vatovec J, Sereg-Bahar M. Histologic changes onstapedial footplate in otosclerosis. Correlations betweenhistologic activity and clinical findings. Otol Neurotol 2003;24 (1): 43-7. doi: 10.1097/00129492-200301000-00010.

9. Quesnel AM, Ishai R, McKenna MJ. Otosclerosis: Temporalbone pathology. Otolaryngol Clin North Am 2018; 51 (2):291-303. doi: 10.1016/j.otc.2017.11.001.

10. Karosi T, Csomor P, Szalmás A, Kónya J, Petkó M, Sziklai I.Osteoprotegerin expression and sensitivity in otosclerosiswith different histological activity. Eur Arch Otorhinolaryngol2011; 268 (3): 357-65. doi: 10.1007/s00405-010-1404-y

11. Uppal S, Bajaj Y, Rustom I, Coatesworth AP. Otosclerosis 1:the aetiopathogenesis of otosclerosis. Int J Clin Pract 2009;63 (10): 1526-30. doi: 10.1111/j.1742-1241.2009.02045.

12. Kanzaki S, Takada Y, Ogawa K, Matsuo K. Bisphosphonatetherapy ameliorates hearing loss in mice lacking osteoprotegerin.J Bone Mineral Res 2009; 24: 43-49.

13. Seist R, Tong M, Landegger LD, Vasilijic S, Hyakusoku H, etal. Regeneration of cochlear synapses by systemic administrationof a bisphosphonate. Front Mol Neurosci 2020;13: 87. doi: 10.3389/fnmol.2020.00087.

14. Kao SY, Kempfle JS, Jensen JB, Perez-Fernandez D, LysaghtAC, Edge AS, et al. Loss of osteoprotegerin expression inthe inner ear causes degeneration of the cochlear nerveand sensorineural hearing loss. Neurobiol Dis 2013; 56:25-33. doi: 10.1016/j.nbd.2013.04.008.

15. Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, Mc-Kenna MJ. Osteoprotegerin in the inner ear may inhibitbone remodeling in the otic capsule. Laryngoscope 2005;115 (1): 172-7. doi: 10.1097/01.mlg.0000150702.28451.35.

16. Quesnel AM, Seton M, Merchant SN, Halpin C, McKennaMJ. Third-generation bisphosphonates for treatment ofsensorineural hearing loss in otosclerosis. Otol Neurotol2012; 33: 1308-1314.

17. Danesh AA, Shahnaz N, Hall JW 3rd. The audiology of otosclerosis.Otolaryngol Clin North Am 2018; 51 (2): 327-342.doi: 10.1016/j.otc.2017.11.007.

18. Jan TA, Remenschneider AK, Halpin C, Seton M, McKennaMJ, Quesnel AM. Third-generation bisphosphonates forcochlear otosclerosis stabilizes sensorineural hearing lossin long-term follow-up. Laryngoscope Investig Otolaryngol2017; 2 (5): 262-268. doi: 10.1002/lio2.91.

19. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonatemechanism of action. Mini Rev Med Chem 2004; 4(7): 711-9.

20. Savino S, Toscano A, Purgatorio R, Profilo E, Laghezza A,Tortorella P, et al. Novel bisphosphonates with antiresorptiveeffect in bone mineralization and osteoclastogenesis.Eur J Med Chem 2018; 158: 184-200. doi: 10.1016/j.ejmech.2018.08.044.

21. Kennedy DW, Hoffer ME, Holliday M. The effects of etidronatedisodium on progressive hearing loss from otosclerosis.Otolaryngol Head Neck Surg 1993; 109 (3 Pt 1): 461-7.doi: 10.1177/019459989310900312.

22. Brookler KH, Tanyeri H. Etidronate for the the neurotologicsymptoms of otosclerosis: preliminary study.Ear Nose Throat J 1997; 76 (6): 371-6, 379-81. DOI:10.1177/014556139707600605-6.